NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

What you said is not quite true either ex.
Marzan stated:

Johns Hopkins endorses DcVax L as SOC is huge.

If you read the article that they are talking role of DC Vaccines in the current standard of care. Here is a relevant except:

5.4. Role of DC Vaccines in Current Standard of Care
As we await the results of these trials, considerations into where DCVs fit into the current standard of care should be evaluated. There is no clear consensus on whether DCVs should be administered before maximal resection, concurrently with temozolomide, after radiation therapy, or any other variations. Each method has pros and cons that ultimately require the use of clinical studies to gain further insight. Historically, novel therapies such as DCVs have been given in the recurrent setting after standard of care consisting of surgical resection followed by adjuvant temozolomide and radiation. While the administration of DCVs after maximal surgical resection is typically advocated due to the idea that decreased tumor burden leads to a decrease in tumor-associated immune suppression and stronger cytotoxic immune response, the timing of DCVs in conjunction with or after adjuvant chemoradiation is less clear [218].

https://www.mdpi.com/2072-6694/11/4/537/htm